Pellentesque lacus vivamus nascetur nunc purus tempus nostra parturient. Fusce tellus congue luctus ullamcorper non accumsan dis dictum. Class nisl vulputate sollicitudin maecenas senectus dolor mattis bibendum potenti commodo. Velit massa vivamus ad ipsum sagittis. Turpis nostra quam quisque sodales efficitur ligula praesent. Iaculis cursus rutrum libero fusce sodales dis quam enim. Efficitur penatibus class...
Pellentesque lacus vivamus nascetur nunc purus tempus nostra parturient. Fusce tellus congue luctus ullamcorper non accumsan dis dictum. Class nisl vulputate sollicitudin maecenas senectus dolor mattis bibendum potenti commodo. Velit massa vivamus ad ipsum sagittis. Turpis nostra quam quisque sodales efficitur ligula praesent. Iaculis cursus rutrum libero fusce sodales dis quam enim. Efficitur penatibus class...
Pellentesque lacus vivamus nascetur nunc purus tempus nostra parturient. Fusce tellus congue luctus ullamcorper non accumsan dis dictum. Class nisl vulputate sollicitudin maecenas senectus dolor mattis bibendum potenti commodo. Velit massa vivamus ad ipsum sagittis. Turpis nostra quam quisque sodales efficitur ligula praesent. Iaculis cursus rutrum libero fusce sodales dis quam enim. Efficitur penatibus class...
Pellentesque lacus vivamus nascetur nunc purus tempus nostra parturient. Fusce tellus congue luctus ullamcorper non accumsan dis dictum. Class nisl vulputate sollicitudin maecenas senectus dolor mattis bibendum potenti commodo. Velit massa vivamus ad ipsum sagittis. Turpis nostra quam quisque sodales efficitur ligula praesent. Iaculis cursus rutrum libero fusce sodales dis quam enim. Efficitur penatibus class...
April 5 – 10, 2024 This year Biofluidica will be exhibiting at AACR (booth #953). If you have any interest in exosomes as biomarkers this will be a good opportunity to meet with us and determine how you can leverage EV analysis as part of your therapeutic development strategy.
February 11 – 14, 2024 BioFluidica, Inc. will be showcased their Fetal Cell-Based DNA Test (in development) at #SMFM2024 from Feb 11-14th! Visitors came to Booth #519 to learn more about their cutting-edge, liquid biopsy rare cell/EV isolation platform’s capabilities and their vision for the future of prenatal (and oncology) testing.
November 3 – 5, 2023 Biofluidica exhibited in San Diego November 1-5 at the Society for Immunotherapy of Cancer’s 39th Annual Meeting. Many researchers stopped the Biofluidica booth to learn more about our next-generation liquid biopsy platform, LiquidScan, a unique fully automated system for isolating and enriching rare cells and exosomes from liquid biopsy samples.
July 17, 2023 BioFluidica is currently seeking pregnant women aged 18 years and older in the early stages of pregnancy, specifically between 7-13 weeks for a prenatal blood study that aims to advance cell-based noninvasive prenatal testing (cbNIPT) by isolating fetal cells from a simple blood draw, providing valuable insights into the baby’s genetic composition....
Chicago, IL, June 3-5, 2023 BioFluidica received a record number of visitors at Booth 27172 at the ASCO 2023 Annual Meeting at the McCormick Center in Chicago. Interest in newer methods for rare cell and EV (exosomes) enrichment has grown as evidenced by the visitors to our booth, from research institutes and commercial interests.
Hu et al., Anal. Chem. 2023 May 16;95(19) 7665-7675 used LiquidScan to affinity capture EVs from plasma of breast cancer patients. Extracellular vesicles (EVs) carry RNA cargo that is believed to be associated with the cell-of-origin and thus have the potential to serve as a minimally invasive liquid biopsy marker for supplying molecular information to...